Danaher Corporation is poised to acquire medical technology company Masimo Corporation for approximately $9.9 billion, according to multiple reports. The transaction, which could be formally announced as early as this week, represents a significant premium to Masimo's current market valuation and marks a major consolidation move within the healthcare diagnostics and monitoring sector.
The proposed acquisition values Masimo at a substantial multiple above its approximately $7 billion market capitalization prior to the announcement. The deal follows notable governance changes at Masimo, including board restructuring driven by activist investor pressure, which may have paved the way for strategic alternatives discussions.
Market reaction to the transaction announcement has been pronounced, with Masimo shares gaining 34.51% as investors priced in the acquisition premium, while Danaher shares declined 5.22% in premarket trading. The deal, if completed, would expand Danaher's portfolio in patient monitoring and healthcare technology, consolidating two significant players in the medical devices industry.